Issue 3 - Jan 19, 2018
  • Guest Editorial

    A unique drug for each patient: a paradigm shift in cancer therapy

    The recent FDA approvals of a cell/gene therapy for patients with advanced B cell malignancies provide a glimpse into a paradigm shift in the treatment of hematologic and solid cancers, the creation of a new drug unique to each cancer patient.

  • News Analysis

    As government shutdown looms, don’t lose sight of bigger battle over appropriations, sequestration

    As the rancor in Washington continues to escalate from bickering to a war on many fronts, the deadline approaches for the end of a continuing resolution that keeps the federal government open until Jan. 19.

  • In Brief

    • Allison, Bax, Doudna and Chang receive NAS prizes
    • Kathy Albain receives first Huizenga Family Endowed Chair at Loyola University Chicago
    • ACS CAN: Cancer patients should be exempt from possible Medicaid work requirements
    • ACCC’s 2017 survey: cost of treatment is top threat to cancer program growth
  • TCCL Logo

  • Clinical Roundup

    • Blood test for eight cancer types provides framework for early detection
    • Study shows screening population for select genes is a cost-effective solution
    • Polygenic hazard score predicts when men develop prostate cancer
    • Exelixis and Ipsen announce phase III trial results of Cabozantinib in advanced hepatocellular carcinoma
  • Drugs and Targets

    • Foundation Medicine and Pfizer form partnership to develop companion diagnostics
    • FDA approves addition of overall survival data to Kyprolis
    • Novartis granted FDA Priority Review for Kymriah for adults with r/r DLBCL
  • CTEP Protocols

    NCI CTEP-Approved Trials for January

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

    For further information, contact the principal investigator listed.

Issue 2 - Jan 12, 2018
Issue 1 - Jan 5, 2018
  • ASCO forms collaboration with two Big Data firms to grow CancerLinQ

    The ten-year collaboration, announced Dec. 21, gives Tempus and PH.AI access to de-identified data from over a growing database of more than a million records contained in CancerLinQ.

    ASCO and its new commercial partners will continue to expand CancerLinQ and, at the same time, look for better ways to aggregate and mine the data. The data could be used in drug development as well as scientific projects and quality initiatives.

  • Conversation with the Cancer Letter

    Hudis: ASCO needed collaborators to help CancerLinQ deliver faster on its mission

    “This is a licensure and a strategic collaboration. This leverages the expertise of several organizations to allow us to deliver real value to our members and subscribers faster than we would have been able to otherwise.”

  • Conversation with the Cancer Letter

    Lefkofsky: CancerLinQ has value in ushering in an era of precision medicine

    “This gets a bit into Tempus’s business model and at least how we view the world. This data has some commercial applicability today. But the real value in this data is in how do you build much larger, much more comprehensive datasets that actually can be used to usher in an era of precision medicine.”

  • Introducing the clinical section of The Cancer Letter

    Today’s issue of The Cancer Letter contains a new section devoted to clinical news.

    As part of our new format, stories that have immediate clinical significance will appear in every issue, much like a sports or business section in a newspaper.

  • An Appreciation

    Jimmie Holland, founder of psycho-oncology, dies at 89

    Jimmie C. Holland, internationally recognized as the founder of the field of psycho-oncology, died suddenly on Dec. 24, 2017, at the age of 89.

  • An Appreciation

    Gerald Hanks, pioneering radiation oncologist, dies at 83

    Gerald E. Hanks was a giant in the world of radiation oncology and oncology in general. It isn’t often that we can say this and probably understate a person’s significance and influence, but Jerry was one of those people.  He died on Dec. 20, 2017, at the age of 83.

  • In Brief

    • Howard “Skip” Burris elected ASCO president for 2019-2020
    • Hochster named associate director, clinical research, and chief of GI med/onc at Rutgers
    • Whitten named president of Taiho Oncology
    • Purdue Center for Cancer Research receives $10 million from Walther Cancer Foundation
    • METAvivor announces 2017 grant awards for metastatic cancer research
    • JAX starts canine cancer initiative to find predictors, treatments for humans, dog
  • TCCL Logo

  • Trials and Tribulations

    Cabozantinib in first-line treatment of metastatic renal cell carcinoma

    Systemic therapies for metastatic renal cell carcinoma (mRCC) have expanded dramatically over the past 3 years.

  • Clinical Roundup

    • CAP publishes guideline to ensure accurate HPV testing in head and neck cancers
    • CAR-T therapy cancer study published in the New England Journal of Medicine
    • Cancer mortality in the U.S. continues decades-long drop
  • Drugs and Targets

    • FDA approves Perjeta in adjuvant breast cancer
    • FDA approves Cabometyx for previously untreated advanced renal cell carcinoma
    • FDA approves Pfizer’s Bosulif (bosutinib) for newly-diagnosed Ph+ CML
    • FDA approves Xgeva for prevention of skeletal-related events in multiple myeloma
    • Kisqali receives breakthrough designation for HR+/HER2- breast cancer
    • FDA accepts sBLA, grants priority review for Adcetris
    • FDA grants breakthrough designation for Avelumab in combination with Inlyta in RCC
    • FDA grants orphan drug designation to Aptose Biosciences for CG’806 in AML
    • FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated NSCLC
    • FDA grants priority review for Apalutamide in non-metastatic castration-resistant prostate cancer
    • Janssen and Legend Biotech enter deal to develop CAR-T therapy